Morphological Macular Changes Under Brolucizumab Treatment for Neovascular Age-Related Macular Degeneration Refractory to Previous Anti-VEGF Treatment Compared with Treatment-Naive Eyes

References

• Lim LS, Mitchell P, Seddon JM, et al. Age-related macular degeneration. Lancet. 2012;379(9827):1728–1738. doi:10.1016/S0140-6736(12)60282-7
   PubMed Web of Science ®Google Scholar
• Bloch SB, Larsen M, Munch IC. Incidence of legal blindness from age-related macular degeneration in Denmark: year 2000 to 2010. Am J Ophthalmol. 2012;153(2):209–213 e2. doi:10.1016/j.ajo.2011.10.016
   PubMed Web of Science ®Google Scholar
• Martin DF, Maguire MG, Fine SL; Comparison of Age-related Macular Degeneration Treatments Trials Research. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119(7):1388–1398. doi:10.1016/j.ophtha.2012.03.053
   PubMed Web of Science ®Google Scholar
• Eleftheriadou M, Vazquez-Alfageme C, Citu CM, et al. Long-term outcomes of aflibercept treatment for neovascular age-related macular degeneration in a clinical setting. Am J Ophthalmol. 2017;174:160–168. doi:10.1016/j.ajo.2016.09.038
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419–1431. doi:10.1056/NEJMoa054481
   PubMed Web of Science ®Google Scholar
• Silva R, Berta A, Larsen M, et al. Treat-and-extend versus monthly regimen in neovascular age-related macular degeneration: results with ranibizumab from the TREND study. Ophthalmology. 2018;125(1):57–65. doi:10.1016/j.ophtha.2017.07.014
   PubMed Web of Science ®Google Scholar
• Pozarowska D, Pozarowski P. The era of anti-vascular endothelial growth factor (VEGF) drugs in ophthalmology, VEGF and anti-VEGF therapy. Cent Eur J Immunol. 2016;3(3):311–316. doi:10.5114/ceji.2016.63132
   Google Scholar
• Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol. 2009;148(1):43–58 e1. doi:10.1016/j.ajo.2009.01.024
   PubMed Web of Science ®Google Scholar
• Abedi F, Wickremasinghe S, Islam AFM, et al. Anti-VEGF treatment in neovascular age-related macular degeneration: a treat-and-extend protocol over 2 years. Retina. 2014;34(8):1531–1538. doi:10.1097/IAE.0000000000000134
   PubMed Web of Science ®Google Scholar
• Spooner KL, Mhlanga C, Hong T, et al. The burden of neovascular age-related macular degeneration: a patient’s perspective. Clin Ophthalmol. 2018;12:2483–2491. doi:10.2147/OPTH.S185052
   PubMed Web of Science ®Google Scholar
• Kim LN, Mehta H, Barthelmes D, et al. Metaanalysis of real-world outcomes of intravitreal ranibizumab for the treatment of neovascular age-related macular degeneration. Retina. 2016;36(8):1418–1431. doi:10.1097/IAE.0000000000001142
   PubMed Web of Science ®Google Scholar
• Okada M, Mitchell P, Finger RP, et al. Nonadherence or nonpersistence to intravitreal injection therapy for neovascular age-related macular degeneration: a mixed-methods systematic review. Ophthalmology. 2021;128(2):234–247. doi:10.1016/j.ophtha.2020.07.060
   PubMed Web of Science ®Google Scholar
• Dugel PU, Koh A, Ogura Y, et al. HAWK and HARRIER: phase 3, multicenter, randomized double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020;127(1):72–84.
   PubMed Web of Science ®Google Scholar
• Spaide RF, Jaffe GJ, Sarraf D, et al. Consensus nomenclature for reporting neovascular age-related macular degeneration data: consensus on neovascular age-related macular degeneration nomenclature study group. Ophthalmology. 2020;127(5):616–636. doi:10.1016/j.ophtha.2019.11.004
   PubMed Web of Science ®Google Scholar
• Leclaire MD, Lauermann J, Alten F, et al. Intraokuläre Entzündung mit okklusiver retinaler Vaskulitis nach intravitrealer Brolucizumab-Injektion [Intraocular inflammation with occlusive retinal vasculitis following intravitreal injection of brolucizumab]. Ophthalmologe. 2022;119(3):296–299. German. doi:10.1007/s00347-021-01341-4
   PubMed Web of Science ®Google Scholar
• Witkin AJ, Hahn P, Murray TG, et al. Occlusive Retinal Vasculitis Following Intravitreal Brolucizumab. J Vitreoretin Dis. 2020;4(4):269–279. doi:10.1177/2474126420930863
   PubMedGoogle Scholar
• Haug SJ, Hien DL, Uludag G, et al. Retinal arterial occlusive vasculitis following intravitreal brolucizumab administration. Am J Ophthalmol Case Rep. 2020;18:100680. doi:10.1016/j.ajoc.2020.100680
   PubMedGoogle Scholar
• Bulirsch LM, Saßmannshausen M, Nadal J, et al. Short-term real-world outcomes following intravitreal brolucizumab for neovascular AMD: SHIFT study. Br J Ophthalmol. 2021;106(9):1288–1294.
   PubMed Web of Science ®Google Scholar
• Book M, Ziegler M, Rothaus K, et al. Erste Erfahrungen mit Brolucizumab bei neovaskulärer altersabhängiger Makuladegeneration und Therapierefraktärität unter der bisherigen Anti-VEGF-Therapie [Real-life experiences with Brolucizumab in recalcitrant neovascular age-related macular degeneration]. Ophthalmologe. 2022;119(3):258–264. German. doi:10.1007/s00347-021-01474-6
   PubMedGoogle Scholar
• Bilgic A, Kodjikian L, March de Ribot F, et al. Real-world experience with brolucizumab in wet age-related macular degeneration: the REBA study. J Clin Med. 2021;10(13):2758. doi:10.3390/jcm10132758
   PubMed Web of Science ®Google Scholar
• Holz FG, Schmitz-Valckenberg S, Wolf A, et al. A randomized, open-label, multicenter study of switching to brolucizumab with or without a loading dose for patients with suboptimal anatomically controlled neovascular age-related macular degeneration-the FALCON study. Graefes Arch Clin Exp Ophthalmol. 2022;260(8):2695–2702. doi:10.1007/s00417-022-05591-z
   PubMed Web of Science ®Google Scholar
• Dugel PU, Jaffe GJ, Sallstig P, et al. Brolucizumab versus aflibercept in participants with neovascular age-related macular degeneration: a randomized trial. Ophthalmology. 2017;124(9):1296–1304. doi:10.1016/j.ophtha.2017.03.057
   PubMed Web of Science ®Google Scholar
• Gale RP, Pearce I, Eter N, et al. Anatomical and functional outcomes following switching from aflibercept to ranibizumab in neovascular age-related macular degeneration in Europe: SAFARI study. Br J Ophthalmol. 2020;104(4):493–499. doi:10.1136/bjophthalmol-2019-314251
   PubMed Web of Science ®Google Scholar
• Simader C, Ritter M, Bolz M, et al. Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration. Ophthalmology. 2014;121(6):1237–1245. doi:10.1016/j.ophtha.2013.12.029
   PubMed Web of Science ®Google Scholar
• Schmidt-Erfurth U, Chong V, Loewenstein A, et al. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol. 2014;98(9):1144–1167. doi:10.1136/bjophthalmol-2014-305702
   PubMed Web of Science ®Google Scholar
• Holz FG, Heinz C, Wolf A, et al. Intraokulare Entzündungen bei Brolucizumab-Anwendung [Intraocular inflammation with brolucizumab use: patient management-diagnosis-therapy]. Ophthalmologe. 2021;118(3):248–256. German. doi:10.1007/s00347-021-01321-8
   PubMed Web of Science ®Google Scholar
• Mones J, Srivastava SK, Jaffe GJ, et al. Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with brolucizumab: post hoc review of HAWK and HARRIER. Ophthalmology. 2021;128(7):1050–1059. doi:10.1016/j.ophtha.2020.11.011
   PubMed Web of Science ®Google Scholar